Vancouver, British Columbia – May 1st, 2023 – GeneTether Therapeutics Inc. (“GeneTether” or the “Company”) (CSE:GTTX), is pleased to announce the engagement of Mr. Gad Berdugo, Managing Partner of Explorium Capital LLC, as an advisor to explore strategic alternatives for its GeneTether™ platform technology. Mr. Berdugo, who served as the former Chief Business Officer of gene editing pioneer, Editas, brings more than 25 years of biotech corporate development, business development, strategy, and financial experience. Among his prior roles, Mr. Berdugo held several executive-level positions for life science companies including serving most recently as CEO of EpiVax Oncology, Inc., a precision cancer immunotherapy company, which he co-founded ; CFO at Nasdaq-listed Immune Pharmaceuticals Inc.; Managing Director and Head of Life Sciences at Tegris Advisors LLC, a New York based advisory boutique, where he led several cross-border M&As and strategic alliances mandates; and Founder and Managing Partner of the Explorium Global Healthcare Fund, providing growth capital to emerging biotech companies.
Earlier in his career, Mr. Berdugo also served as Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group and as a Director of Global Business Development within Baxter Healthcare’s biopharma group. Mr. Berdugo started his career at Abbott Laboratories.
Mr. Berdugo received his M.B.A. from H.E.C. School of Management in Paris, his M.Sc. in Biochemical Engineering from University College London, and his B.Sc. with Honors in Biotechnology from Imperial College London.
“We are very happy to welcome Gad to our team to lead the exploration of strategic alternatives for our GeneTether™ platform technology,” said Roland Boivin, CEO of GeneTether. “We believe that his extensive experience in the biotechnology industry coupled with his deep understanding of gene editing technologies and the various organizations that are working in the field will be invaluable as we explore opportunities to maximize the potential of our platform.”
Mr. Berdugo stated, “I am excited to begin working with the GeneTether team to maximize the value of their GeneTether™ platform technology. This innovative technology has tremendous potential to make a positive impact on rates of gene editing via homology-directed repair, which would be a significant and critical step forward in the field of gene editing. I look forward to working with the team, including GeneTether’s co-founder and director, Dr. Bill Garner, who I’ve known for many years.”
Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., and veteran gene editing researcher, R. Geoffrey Sargent, Ph.D., GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. The Company’s wholly-owned GeneTether™ platform technology uses a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. The Company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases.
For more information, visit www.genetether.com.
About Explorium Capital LLC
Founded by Mr. Gad Berdugo, MSc Eng. MBA, Exploriun Capital provides global strategic and financial advisory services as well as seed investments, to early-stage biotechnology ventures.
For more information, visit www.exploriumcapital.com.
Roland Boivin, CEO
(833) 294-4363 ext. 1
Jean Jen, CFO and Corporate Secretary
(833) 294-4363 ext. 2
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause GeneTether’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.
Forward-looking statements in this document include the expectation that the Company will identify and pursue a strategic alternative and all other statements that are not statements of historical fact.
Although GeneTether believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
The Canadian Securities Exchange nor its Regulation Service has approved nor disapproved the contents of this news release.